SIA
CRL icon

SkyView Investment Advisors’s Charles River Laboratories CRL Stock Holding History

SkyView Investment Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1
Closed – – 779
2023
Q1 		$0 Buy
+1
New +$227 ﹤0.01% 682

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

SkyView Investment Advisors's CRL Position: Q2 2023 in Review

SkyView Investment Advisors sold out of Charles River Laboratories (CRL) in Q2 2023, closing a stake of 1 share.

SkyView Investment Advisors first reported a position in CRL in Q1 2023 and held it in 1 quarter. The position peaked at $0 in Q1 2023. 612 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

  • SkyView Investment Advisors reported no remaining Charles River Laboratories position as of Q2 2023 after selling out during the quarter.
  • SkyView Investment Advisors sold 1 Charles River Laboratories share in Q2 2023.
  • SkyView Investment Advisors first reported a position in Charles River Laboratories in Q1 2023 and held it in 1 quarter.
  • SkyView Investment Advisors's Charles River Laboratories position peaked at $0 in Q1 2023.
  • 612 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on SkyView Investment Advisors's 13F filing for Q2 2023, filed 15 Aug 2023.